Exagen Q1 2026: Record revenue $17.3M, net loss $4.0M; FY guidance reaffirmed

EXAGEN INC.

2026-Q1 EPS reported -$0.17 revenue$17,306,000

Revenue rose 12% YoY to $17.3M; net loss widened to $4.0M from $3.8M.
AVISE CTD test volume increased 10% YoY; TTM ASP rose 6% to $444.
Adjusted EBITDA loss improved 14% to $2.2M; cash $21.5M, ahead of expectations.
Full-year 2026 revenue guidance reaffirmed at $70M-$73M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income Net loss $ (3,967). Guidance reaffirmed.

Period: the three months ended March 31, 2026
Revenue: $17.3 million
Net income: Net loss $ (3,967)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Trailing-twelve-month average selling price (ASP) $ 444 $ 419 Cash and cash equivalents $ 21,513 $ 11,194 First Quarter 2026 Highlights: • Achieved record total revenue of $17.3 million, an increase of 12% compared to first quarter 2025. • Grew AVISE CTD test volume 10% compared to first quarter 2025. • Expanded AVISE CTD trailing-twelve-month ASP to $444 per

View on SEC.gov

Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.